NASDAQ:OVAS - OvaScience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.8020 +0.01 (+1.26 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$0.8020
Today's Range$0.7642 - $0.8180
52-Week Range$0.70 - $1.65
Volume269,044 shs
Average Volume432,957 shs
Market Capitalization$29.38 million
P/E Ratio-0.61
Dividend YieldN/A
Beta3.34
OvaScience logoOvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility. The company offers various fertility treatment options, including OvaPrime treatment to restore a woman's egg production by isolating a woman's own EggPC cells within her ovary to mature in vivo into healthy and fertilizable eggs; OvaTure treatment to mature EggPC cells into fertilizable eggs in vitro or outside the body by eliminating the need for hormone stimulation; and AUGMENT treatment to enhance the fertilization and pregnancy rates by using mitochondria from a woman's own EggPC cells. It also provides OvaXon for the prevention of inherited diseases for human and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Receive OVAS News and Ratings via Email

Sign-up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OVAS
CUSIPN/A
Phone617-500-2802

Debt

Debt-to-Equity RatioN/A
Current Ratio11.43
Quick Ratio11.43

Price-To-Earnings

Trailing P/E Ratio-0.61
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00
Price / Sales98.98
Cash FlowN/A
Price / CashN/A
Book Value$1.80 per share
Price / Book0.45

Profitability

EPS (Most Recent Fiscal Year)($1.32)
Net Income$-50,970,000.00
Net Margins-11,175.59%
Return on Equity-47.19%
Return on Assets-42.13%

Miscellaneous

Employees36
Outstanding Shares35,790,000
Market Cap$29.38 million

OvaScience (NASDAQ:OVAS) Frequently Asked Questions

What is OvaScience's stock symbol?

OvaScience trades on the NASDAQ under the ticker symbol "OVAS."

How were OvaScience's earnings last quarter?

OvaScience Inc (NASDAQ:OVAS) announced its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.08. The biotechnology company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.25 million. OvaScience had a negative net margin of 11,175.59% and a negative return on equity of 47.19%. The firm's quarterly revenue was down 73.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.66) earnings per share. View OvaScience's Earnings History.

When is OvaScience's next earnings date?

OvaScience is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for OvaScience.

What price target have analysts set for OVAS?

1 brokerages have issued 12-month price objectives for OvaScience's shares. Their forecasts range from $15.00 to $15.00. On average, they expect OvaScience's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 1,770.3% from the stock's current price. View Analyst Price Targets for OvaScience.

What is the consensus analysts' recommendation for OvaScience?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OvaScience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OvaScience.

What are Wall Street analysts saying about OvaScience stock?

Here are some recent quotes from research analysts about OvaScience stock:
  • 1. HC Wainwright analysts commented, "Refocus on Science Should Aid in the Long Term; Reit Buy Incremental progress as the company seeks to capitalize upon its internal expertise in cell biology. On yesterday’s 4Q17 call, the company provided an update on the OvaPrime and OvaTure programs as management pivoted to a R&D-focused strategy. We think the key takeaways are two-fold: (1) the interim data from the first 20 patients in the Phase 1 trial of OvaPrime appear to deliver bittersweet news. The safety data look clean, but no strong signals were observed on the secondary endpoints that could suggest efficacy. As a result, this trial has terminated patient enrollment, and per management, the company will advance OvaPrime directly to a Phase 1b/2a study in 2H18 with an improved cell processing technique to hopefully improve efficacy." (3/16/2018)
  • 2. According to Zacks Investment Research, "OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. " (1/11/2018)

Who are some of OvaScience's key competitors?

Who are OvaScience's key executives?

OvaScience's management team includes the folowing people:
  • Dr. Christopher A. Kroeger, CEO, Pres, Sec. & Director (Age 50)
  • Dr. Michelle Dipp, Co-Founder & Advisor (Age 42)
  • Mr. Richard H. Aldrich, Co-Founder & Lead Independent Director (Age 64)
  • Mr. Jonathan Gillis, Sr. VP of Fin. & Treasurer (Age 37)
  • Dr. Jonathan L. Tilly Ph.D., Co-Founder and Advisor (Age 55)

Has OvaScience been receiving favorable news coverage?

Media coverage about OVAS stock has trended somewhat negative this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OvaScience earned a news and rumor sentiment score of -0.01 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.15 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for OvaScience.

Who are OvaScience's major shareholders?

OvaScience's stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.97%) and BlackRock Inc. (1.06%). View Institutional Ownership Trends for OvaScience.

Which institutional investors are selling OvaScience stock?

OVAS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for OvaScience.

Which institutional investors are buying OvaScience stock?

OVAS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for OvaScience.

How do I buy shares of OvaScience?

Shares of OVAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OvaScience's stock price today?

One share of OVAS stock can currently be purchased for approximately $0.8020.

How big of a company is OvaScience?

OvaScience has a market capitalization of $29.38 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-50,970,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. OvaScience employs 36 workers across the globe.

How can I contact OvaScience?

OvaScience's mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 617-500-2802 or via email at [email protected]


MarketBeat Community Rating for OvaScience (NASDAQ OVAS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe OVAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.